Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
View original at globenewswire.com“Cash, cash equivalents and fixed-term deposits of $225 million as of September 30, 2025”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
100% of target Phase 2 population became transplant eligible after lasme-cel treatment
80% confidenceExpanded peak sales for lasme-cel could reach up to approximately $1.3 billion with label expansion to 2nd line and 1st line MRD+ consolidation
80% confidencePeak gross sales for lasme-cel could reach up to approximately $700 million in 2035 in US, EU4, and UK markets
80% confidenceApproximately 1,100 B-ALL patients would be treated annually at peak sales
80% confidenceCellectis is strengthening leadership in allogeneic CAR-T innovation with a transformative year ahead
80% confidenceAllogeneic approach enables attractive margins and drives CAR-T B-ALL market growth
80% confidenceTALEB technology shows no bias towards off-site C-to-T editing at CTCF binding sites in primary T cells
80% confidencePromising data from core clinical product candidates demonstrates ability to induce deep and meaningful responses in areas of high unmet medical needs
80% confidenceCssDNA-edited HSPCs show higher engraftment propensity versus AAV-edited HSPCs in murine model
80% confidence
